As of 2024-12-13, the EV/EBITDA ratio of Gritstone Oncology Inc (GRTS) is 0.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. GRTS's latest enterprise value is -7.50 mil USD. GRTS's TTM EBITDA according to its financial statements is -124.44 mil USD. Dividing these 2 quantities gives us the above GRTS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.1x | 13.8x |
| Forward P/E multiples | 15.2x - 21.1x | 15.5x |
| Fair Price | (20.96) - (20.77) | (20.20) |
| Upside | -65190.8% - -64587.9% | -62822.5% |
| Date | EV/EBITDA |
| 2024-11-22 | 0.07 |
| 2024-11-21 | 0.06 |
| 2024-11-20 | 0.06 |
| 2024-11-19 | 0.07 |
| 2024-11-18 | 0.07 |
| 2024-11-15 | 0.07 |
| 2024-11-14 | 0.07 |
| 2024-11-13 | 0.06 |
| 2024-11-12 | 0.06 |
| 2024-11-11 | 0.06 |
| 2024-11-08 | 0.07 |
| 2024-11-07 | 0.06 |
| 2024-11-06 | 0.07 |
| 2024-11-05 | 0.07 |
| 2024-11-04 | 0.06 |
| 2024-11-01 | 0.06 |
| 2024-10-31 | 0.07 |
| 2024-10-30 | 0.07 |
| 2024-10-29 | 0.07 |
| 2024-10-28 | 0.07 |
| 2024-10-25 | 0.07 |
| 2024-10-24 | 0.06 |
| 2024-10-23 | 0.07 |
| 2024-10-22 | 0.07 |
| 2024-10-21 | 0.06 |
| 2024-10-18 | 0.05 |
| 2024-10-17 | 0.05 |
| 2024-10-16 | 0.04 |
| 2024-10-15 | 0.03 |
| 2024-10-14 | 0.04 |
| 2024-10-11 | 0.05 |
| 2024-10-10 | 0.04 |
| 2024-10-09 | -0.06 |
| 2024-10-08 | -0.06 |
| 2024-10-07 | -0.05 |
| 2024-10-04 | -0.05 |
| 2024-10-03 | -0.06 |
| 2024-10-02 | -0.07 |
| 2024-10-01 | -0.08 |
| 2024-09-30 | -0.33 |
| 2024-09-27 | -0.35 |
| 2024-09-26 | -0.36 |
| 2024-09-25 | -0.35 |
| 2024-09-24 | -0.34 |
| 2024-09-23 | -0.34 |
| 2024-09-20 | -0.37 |
| 2024-09-19 | -0.37 |
| 2024-09-18 | -0.31 |
| 2024-09-17 | -0.32 |
| 2024-09-16 | -0.32 |